Cargando…
Target Adverse Event Profiles for Predictive Safety in the Postmarket Setting
We improved a previous pharmacological target adverse‐event (TAE) profile model to predict adverse events (AEs) on US Food and Drug Administration (FDA) drug labels at the time of approval. The new model uses more drugs and features for learning as well as a new algorithm. Comparator drugs sharing s...
Autores principales: | Schotland, Peter, Racz, Rebecca, Jackson, David B., Soldatos, Theodoros G., Levin, Robert, Strauss, David G., Burkhart, Keith |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8246740/ https://www.ncbi.nlm.nih.gov/pubmed/33090463 http://dx.doi.org/10.1002/cpt.2074 |
Ejemplares similares
-
Target‐Adverse Event Profiles to Augment Pharmacovigilance: A Pilot Study With Six New Molecular Entities
por: Schotland, Peter, et al.
Publicado: (2018) -
Predicting potential adverse events using safety data from marketed drugs
por: Daluwatte, Chathuri, et al.
Publicado: (2020) -
Association Between Serotonin Syndrome and Second‐Generation Antipsychotics via Pharmacological Target‐Adverse Event Analysis
por: Racz, Rebecca, et al.
Publicado: (2018) -
In Silico Profiling of Clinical Phenotypes for Human Targets Using Adverse Event Data
por: Soldatos, Theodoros G., et al.
Publicado: (2018) -
Radioimmunotherapy in Non-Hodgkin’s Lymphoma: Retrospective Adverse Event Profiling of Zevalin and Bexxar
por: Sachpekidis, Christos, et al.
Publicado: (2019)